Report from the 63rd Annual American Society of Hematology Meeting — Malignant Hematology

Highlights of the latest research.

Presenters at the 2021 meeting of the American Society of Hematology (ASH; December 11–14, 2021) reported the latest research in hematology. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. Michael E. Williams describes the key findings in hematologic malignancies.

Axi-Cel Improves Event-Free Survival in Early Relapsed/Refractory Large B-Cell Lymphoma

In patients with relapsed/refractory large B-cell lymphoma (LBCL) after first-line chemoimmunotherapy, axicabtagene ciloleucel (axi-cel) offers an event-free-survival advantage over standard care, according to the industry-funded, phase 3 ZUMA-7 trial (abstract 2). The trial was published in the New England Journal of Medicine. Axi-cel is an autologous anti-CD19 chimeric ant…

Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee